<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9763">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05690724</url>
  </required_header>
  <id_info>
    <org_study_id>AFCRO-155</org_study_id>
    <nct_id>NCT05690724</nct_id>
  </id_info>
  <brief_title>Healthy Adults With Mild Cognitive Impairment (MCI) and a 16-week Intervention With Mitocholine™, a Functional Food Ingredient</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel-group Study in Otherwise Healthy Adults With Mild Cognitive Impairment (MCI) Assessing a 16-week Intervention With Mitocholine™, a Functional Food Ingredient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitocholine Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlantia Food Clinical Trials</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mitocholine Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of 16-weeks consumption of Mitocholine on Executive Function and&#xD;
      Homocysteine levels in a population experiencing Mild Cognitive Impairment. The study will&#xD;
      also include measures of memory, language, S-adenosylmethionone (SAM), Betaine, Choline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2023</start_date>
  <completion_date type="Anticipated">March 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, double-blinded, placebo-controlled, parallel proof of concept study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute change in Executive Function Score in the Mitocholine group compared to the Placebo group.</measure>
    <time_frame>Baseline to end of intervention (week 16)</time_frame>
    <description>Assessed by the verbal fluency, colour-word interference and trail making tests in the Delis-Kaplan Executive Function System</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in Homocysteine levels in the Mitocholine group compared to the Placebo group.</measure>
    <time_frame>Baseline to end of intervention (week 16)</time_frame>
    <description>Assessed by serum Homocysteine levels (umol/L)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Memory outcomes (visual memory) in the Mitocholine group compared to the Placebo group</measure>
    <time_frame>Baseline to end of intervention (week 16)</time_frame>
    <description>Assessed by a Paired Associated Learning Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Memory outcomes (episodic memory) in the Mitocholine group compared to the Placebo group</measure>
    <time_frame>Baseline to end of intervention (week 16)</time_frame>
    <description>Assessed by a Word Recall Task</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Language outcomes in the Mitocholine group compared to the Placebo group</measure>
    <time_frame>Baseline to end of intervention (week 16)</time_frame>
    <description>Assessed by the Boston Naming Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in S-adenosylmethionone (SAM) levels in the Mitocholine group compared to the Placebo group</measure>
    <time_frame>Baseline to end of intervention (week 16)</time_frame>
    <description>Assessed by S-adenosylmethionone (SAM) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Betaine levels in the Mitocholine group compared to the Placebo group</measure>
    <time_frame>Baseline to end of intervention (week 16)</time_frame>
    <description>Assessed by Betine in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Choline levels in the Mitocholine group compared to the Placebo group</measure>
    <time_frame>Baseline to end of intervention (week 16)</time_frame>
    <description>Assessed by Choline in blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Mitocholine™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mitocholine™ is a novel formulation of three nutrients choline, succinic acid, and nicotinamide (a vitamin B3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The Placebo product will be identical in appearance and taste to the investigational product</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mitocholine™ or Placebo</intervention_name>
    <description>Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.</description>
    <arm_group_label>Mitocholine™</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing to participate in the study and comply with its procedures.&#xD;
&#xD;
          2. Able to give written informed consent.&#xD;
&#xD;
          3. Adults aged 55 to 79 years, inclusive.&#xD;
&#xD;
          4. Meet MCI criteria, based on the Peterson criteria (Peterson et al., 1999):&#xD;
&#xD;
               1. Presence of a subjective memory complaint as assessed by MAC-Q (score &gt;25).&#xD;
&#xD;
               2. Objective evidence of cognitive impairment as assessed by MoCA (score ≥18 to&#xD;
                  ≤24).&#xD;
&#xD;
               3. Absence of major depression as assessed by PHQ (score &lt;10).&#xD;
&#xD;
               4. Activities of daily living score&#xD;
&#xD;
                    -  males ≥4&#xD;
&#xD;
                    -  females ≥7&#xD;
&#xD;
          5. Have a homocysteine level ≥11.0μmol/L (Smith D et al, 2018).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of a major cognitive disorder (e.g. Alzheimer's or Parkinson's disease&#xD;
             diagnoses; additionally, confirmation of a mini stroke (TIA) within the last 3 months&#xD;
             would be an exclusionary condition).&#xD;
&#xD;
          2. Participants who are pregnant or wish to become pregnant during the trial.&#xD;
&#xD;
          3. Participants who are lactating and/or currently breastfeeding.&#xD;
&#xD;
          4. Participants currently of childbearing potential, but not using an effective method of&#xD;
             contraception, as determined by the investigator.&#xD;
&#xD;
          5. Participants with active or a history of alcohol or substance abuse; (exclude elevated&#xD;
             Gamma GT &amp; clinically abnormal liver function test).&#xD;
&#xD;
          6. Uncontrolled diabetes (or glycated haemoglobin &gt;7% / 53 mmol/mol).&#xD;
&#xD;
          7. Clinically significant heart, liver, or renal disease (at the discretion of the&#xD;
             investigator).&#xD;
&#xD;
          8. Have uncontrolled hypertension SBP &gt; 160mmHg, DBP &gt; 100mmHg).&#xD;
&#xD;
          9. Participants prescribed medications likely to influence memory or mood, as determined&#xD;
             by the investigator.&#xD;
&#xD;
         10. Participants with a history of depression (within past 24 months) or any concurrent&#xD;
             medical, cognitive or psychiatric condition that would either: compromise his/her&#xD;
             ability to comply with the study requirements, may pose significant risk to the&#xD;
             participant, or be deemed exclusionary by the investigator&#xD;
&#xD;
         11. Have had any other condition or are taking a medication that the investigator believes&#xD;
             would interfere with the objectives of the study, pose a safety risk, or confound the&#xD;
             interpretation of the study results.&#xD;
&#xD;
         12. Change in supplements, medication, or major diet in 30 days prior to enrolment and&#xD;
             throughout the study.&#xD;
&#xD;
         13. Taking any supplements or vitamins notably known to affect cognitive function (e.g.&#xD;
             Living Nutrition Cognitive, Viridian Cognitive Complex, ginkgo biloba, fish oil etc.,&#xD;
             list not exhaustive), or any psychotropic medications and products which interact with&#xD;
             acetylcholine esterase and/or NMDA receptors (6-week washout before screening).&#xD;
             Vitamin D and Calcium supplements permitted if on a stable dose for the previous 3&#xD;
             months.&#xD;
&#xD;
         14. Smokers (&gt;5 cigs per week) or participants who use vape products.&#xD;
&#xD;
         15. Has received treatment involving experimental drugs in the past 3 months.&#xD;
&#xD;
         16. Have a malignant disease or any concomitant end-stage organ disease, which, in the&#xD;
             Investigator's judgment, contraindicates participation in the study.&#xD;
&#xD;
         17. Individuals who, in the opinion of the investigator, are considered to be poor&#xD;
             clinical attendees or unlikely for any reason to be able to comply with the trial.&#xD;
&#xD;
         18. Any Participant who is an employee of the study site or an Atlantia Clinical Trials&#xD;
             employee or their close family member or a member of their household.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Morrison</last_name>
    <role>Study Director</role>
    <affiliation>Mitocholine Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eile Butler</last_name>
    <phone>+353 21 430 7442</phone>
    <email>ebutler@atlantiatrials.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atlantia Clinical Trials</name>
      <address>
        <city>Cork</city>
        <state>Munster</state>
        <zip>T23R50R</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eile Butler</last_name>
      <phone>+353214307442</phone>
      <email>ebutler@atlantiatrials.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Dinan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 6, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>March 13, 2023</last_update_submitted>
  <last_update_submitted_qc>March 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

